Who Paid My Doc
Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis
Research payments
$3,102,812
Through program year 2024, $3,102,812 in research payments was reported against Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis, across 486 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $50,721 | 6 |
| 2023 | Research | $203,469 | 62 |
| 2022 | Research | $1,084,236 | 187 |
| 2021 | Research | $1,764,386 | 231 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Hugh Windom Sarasota, FL Named on 34 payments
- Matthew Zirwas Columbus, OH Named on 33 payments
- Vlada Groysman Hoover, AL Named on 31 payments
- Adam Plotkin Delray Beach, FL Named on 29 payments
- Enrique Hanabergh Miami, FL Named on 26 payments
- Eduardo Weiss Hollywood, FL Named on 25 payments
- William Greisner Lexington, KY Named on 25 payments
- Paul Getz West Dundee, IL Named on 24 payments
- Richard Beasley Rapid City, SD Named on 22 payments
- Mirwais Saifi Santee, CA Named on 22 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.